These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35031100)

  • 1. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.
    Neumann PJ; Podolsky MI; Basu A; Ollendorf DA; Cohen JT
    Value Health; 2022 Jan; 25(1):59-68. PubMed ID: 35031100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic impact of the transition from branded to generic oncology drugs.
    Cheung WY; Kornelsen EA; Mittmann N; Leighl NB; Cheung M; Chan KK; Bradbury PA; Ng RCH; Chen BE; Ding K; Pater JL; Tu D; Hay AE
    Curr Oncol; 2019 Apr; 26(2):89-93. PubMed ID: 31043808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
    Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
    Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies.
    Cohen JT
    Value Health; 2023 Mar; 26(3):344-350. PubMed ID: 36336585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.
    Serra-Burriel M; Martin-Bassols N; Perényi G; Vokinger KN
    JAMA Health Forum; 2024 Aug; 5(8):e242530. PubMed ID: 39150730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates.
    Pandya A; Paulden M; Zhu J; Lavelle TA; Hammitt J
    Med Decis Making; 2022 Oct; 42(7):885-892. PubMed ID: 35531945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses.
    Levy J; Rosenberg M; Vanness D
    Value Health; 2018 Jun; 21(6):677-684. PubMed ID: 29909872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening.
    O'Mahony JF; Naber SK; Normand C; Sharp L; O'Leary JJ; de Kok IM
    Value Health; 2015 Dec; 18(8):1138-51. PubMed ID: 26686801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review on the quality, validity and usefulness of current cost-effectiveness studies for treatments of neovascular age-related macular degeneration.
    Elshout M; Webers CAB; van der Reis MI; Schouten JSAG
    Acta Ophthalmol; 2018 Dec; 96(8):770-778. PubMed ID: 29862641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.
    Grima DT; Bernard LM; Dunn ES; McFarlane PA; Mendelssohn DC
    Pharmacoeconomics; 2012 Nov; 30(11):981-9. PubMed ID: 22946789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Industry sponsorship bias in cost effectiveness analysis: registry based analysis.
    Xie F; Zhou T
    BMJ; 2022 Jun; 377():e069573. PubMed ID: 35732297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research.
    Am J Respir Crit Care Med; 2002 Feb; 165(4):540-50. PubMed ID: 11850349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
    Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
    Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.
    Vallejo-Torres L; García-Lorenzo B; Edney LC; Stadhouders N; Edoka I; Castilla-Rodríguez I; García-Pérez L; Linertová R; Valcárcel-Nazco C; Karnon J
    Appl Health Econ Health Policy; 2022 May; 20(3):337-349. PubMed ID: 34964092
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.